Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Immune Response Against Viral Pathogens

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors.

Cancer communications (London, England)·2025

Same author

Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.

Blood advances·2024

Same author

Impaired T cells and "memory-like" NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation.

Blood advances·2024

Same author

Identification of novel canonical and cryptic HCMV-specific T-cell epitopes for HLA-A∗03 and HLA-B∗15 via peptide-PRISM.

Blood advances·2023

Same author

C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Hematological Malignancies-Myeloablative Effects, Antilymphoma Activity, and Safety Profile.

Clinical nuclear medicine·2023

Same author

CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis.

Frontiers in immunology·2023

Search research articles

Related Experiment Video

Updated: May 29, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Adoptive immunotherapy with virus-specific T cells.

Shigeo Fuji¹, Markus Kapp, Götz Ulrich Grigoleit

¹Department of Internal Medicine II, Division of Hematology, University Hospital of Würzburg, Josef-Schneider-Straße 2, Würzburg, Germany.

Best Practice & Research. Clinical Haematology

|September 20, 2011

Summary

This summary is machine-generated.

Adoptive immunotherapy shows promise for controlling viral infections like cytomegalovirus and Epstein-Barr virus in stem cell transplant patients. This approach restores immune defenses, improving outcomes for those with weakened immunity.

More Related Videos

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

Related Experiment Videos

Last Updated: May 29, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

Area of Science:

Immunology
Virology
Hematology

Background:

Viral infections pose significant risks for immunosuppressed patients post-allogeneic hematopoietic stem cell transplantation (HSCT).
Common culprits include cytomegalovirus, adenovirus, and Epstein-Barr virus, with emerging concerns from polyomavirus and human herpesvirus 6.
Delayed recovery of virus-specific cellular immunity correlates with increased risk of viral reactivation and disease.

Purpose of the Study:

To review the current landscape of adoptive immunotherapy for managing viral infections after HSCT.
To highlight the safety and efficacy of adoptive immunotherapy in clinical trials.

Main Methods:

Literature review of recent clinical trials and studies on adoptive immunotherapy for viral diseases post-HSCT.
Focus on viral infections including cytomegalovirus, adenovirus, Epstein-Barr virus, and polyomavirus.

Main Results:

Adoptive immunotherapy has demonstrated safety and effectiveness in clinical settings.
This therapeutic strategy can restore virus-specific cellular immunity, crucial for controlling viral reactivation.

Conclusions:

Adoptive immunotherapy is a viable and attractive option for treating viral diseases in HSCT recipients.
Further application of this approach is warranted to mitigate viral morbidity and mortality in immunocompromised populations.